Patents by Inventor Kris Holt

Kris Holt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ST-246 (tecovirimat monohydrate) suspension formulations
    Patent number: 11779566
    Abstract: The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: October 10, 2023
    Assignee: Siga Technologies, Inc.
    Inventors: Shanthakumar R. Tyavanagimatt, Kris Holt, Ying Tan, Melialani A. C. L. S. Anderson, Dennis E. Hruby
  • ST-246 (tecovirimat monohydrate) SUSPENSION FORMULATIONS
    Publication number: 20230016581
    Abstract: The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.
    Type: Application
    Filed: July 14, 2022
    Publication date: January 19, 2023
    Applicant: SIGA TECHNOLOGIES, INC.
    Inventors: Shanthakumar R. TYAVANAGIMATT, Kris HOLT, Ying TAN, Melialani A.C.L.S. ANDERSON, Dennis E. HRUBY
  • ST-246 (tecovirimat monohydrate) suspension formulations
    Patent number: 11433051
    Abstract: The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: September 6, 2022
    Assignee: Siga Technologies, Inc.
    Inventors: Shanthakumar R. Tyavanagimatt, Kris Holt, Ying Tan, Melialani A. C. L. S. Anderson, Dennis E. Hruby
  • ST-246 (tecovirimat monohydrate) SUSPENSION FORMULATIONS
    Publication number: 20210212987
    Abstract: The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.
    Type: Application
    Filed: February 15, 2017
    Publication date: July 15, 2021
    Applicant: SIGA TECHNOLOGIES, INC.
    Inventors: Shanthakumar R. TYAVANAGIMATT, Kris HOLT, Ying TAN, Melialani A.C.L.S. ANDERSON, Dennis E. HRUBY
  • NANOPARTICLE PHARMACEUTICAL FORMULATIONS
    Publication number: 20110268775
    Abstract: The present invention is directed to methods of preparing nanoparticles of aqueous-insoluble compounds, particularly aqueous-insoluble bioactive (drug) compounds, and to compositions and medicaments obtained by these methods. These methods, compositions, and other inventive aspects of the present invention are based particularly on the use of bile acid compound(s) to prepare nanoparticles of aqueous-insoluble compounds.
    Type: Application
    Filed: January 5, 2010
    Publication date: November 3, 2011
    Applicant: PHARMANOVA, INC.
    Inventors: Kris Holt, Deepak Thassu, Michael R. Violante